A double blind comparison of diclofenac and indomethacin in the treatment of ankylosing spondylitis.

摘要: During almost 12 years of development and clinical trials, diclofenac sodium has been shown to be both effective safe as a new nonsteroidal antiinflammatory drug (NSAID) for the treatment rheumatic diseases including ankylosing spondylitis (AS). We compared safety efficacy 75, 100, or 125 mg/day with same doses indomethacin in multicenter, randomized, parallel group trial patients AS. A single blind placebo washout period 2 days weeks preceded 13-week double period. Both produced significant (p less than 0.001) improvement from baseline all 14 variables analyzed. There were no between differences. Differences favored frequency severity adverse experiences reported complaints affecting central nervous system.